The bacterial lysate OM-85 engages Toll-like receptors 2 and 4 triggering an immunomodulatory gene signature in human myeloid cells.


Journal

Mucosal immunology
ISSN: 1935-3456
Titre abrégé: Mucosal Immunol
Pays: United States
ID NLM: 101299742

Informations de publication

Date de publication:
04 Mar 2024
Historique:
received: 01 09 2023
revised: 02 02 2024
accepted: 26 02 2024
pubmed: 7 3 2024
medline: 7 3 2024
entrez: 6 3 2024
Statut: aheadofprint

Résumé

OM-85 is a bacterial lysate used in clinical practice to reduce duration and frequency of recurrent respiratory tract infections. Whereas knowledge of its regulatory effects in vivo has substantially advanced, the mechanisms of OM-85 sensing remain inadequately addressed. Here, we show that the immune response to OM-85 in the mouse is largely mediated by myeloid immune cells through Toll-like receptor (TLR) 4 in vitro and in vivo. Instead, in human immune cells, TLR2 and TLR4 orchestrate the response to OM-85, which binds to both receptors as shown by surface plasmon resonance assay. Ribonucleic acid-sequencing analyses of human monocyte-derived dendritic cells reveal that OM-85 triggers a pro-inflammatory signature and a unique gene set, which is not induced by canonical agonists of TLR2 or TLR4 and comprises tolerogenic genes. A largely overlapping TLR2/4-dependent gene signature was observed in individual subsets of primary human airway myeloid cells, highlighting the robust effects of OM-85. Collectively, our results suggest caution should be taken when relating murine studies on bacterial lysates to humans. Furthermore, our data shed light on how a standardized bacterial lysate shapes the response through TLR2 and TLR4, which are crucial for immune response, trained immunity, and tolerance.

Identifiants

pubmed: 38447907
pii: S1933-0219(24)00019-9
doi: 10.1016/j.mucimm.2024.02.010
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.

Auteurs

Hanif J Khameneh (HJ)

Università della Svizzera Italiana (USI), Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Bellinzona, Switzerland. Electronic address: hanif.javanmard@irb.usi.ch.

Marco Bolis (M)

Università della Svizzera Italiana (USI), Faculty of Biomedical Sciences, Institute of Oncology Research, Bellinzona, Switzerland; Computational Oncology Unit, Department of Oncology, Istituto di Richerche Farmacologiche 'Mario Negri' IRCCS, Milano, Italy; Bioinformatics Core Unit, Swiss Institute of Bioinformatics, Bellinzona, Switzerland.

Pedro M O Ventura (PMO)

Università della Svizzera Italiana (USI), Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Bellinzona, Switzerland.

Giada A Cassanmagnago (GA)

Computational Oncology Unit, Department of Oncology, Istituto di Richerche Farmacologiche 'Mario Negri' IRCCS, Milano, Italy.

Berenice A Fischer (BA)

Università della Svizzera Italiana (USI), Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Bellinzona, Switzerland.

Alessandro Zenobi (A)

Università della Svizzera Italiana (USI), Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Bellinzona, Switzerland.

Jessica Guerra (J)

Università della Svizzera Italiana (USI), Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Bellinzona, Switzerland.

Irene Buzzago (I)

Università della Svizzera Italiana (USI), Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Bellinzona, Switzerland.

Maurizio Bernasconi (M)

Pulmonology Division, Ente Ospedaliero Cantonale (EOC), Ospedale Regionale di Bellinzona e Valli (ORBV), Bellinzona, Switzerland.

Guido J R Zaman (GJR)

Oncolines B.V., AB Oss, The Netherlands.

Andrea Rinaldi (A)

Università della Svizzera Italiana (USI), Faculty of Biomedical Sciences, Institute of Oncology Research, Bellinzona, Switzerland.

Simone G Moro (SG)

Università della Svizzera Italiana (USI), Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Bellinzona, Switzerland.

Federica Sallusto (F)

Università della Svizzera Italiana (USI), Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Bellinzona, Switzerland; Institute of Microbiology, ETH Zurich, Zurich, Switzerland.

Edouard Baulier (E)

OM Pharma SA, Department of Preclinical Research, Meyrin, Switzerland.

Christian Pasquali (C)

OM Pharma SA, Department of Preclinical Research, Meyrin, Switzerland.

Greta Guarda (G)

Università della Svizzera Italiana (USI), Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Bellinzona, Switzerland. Electronic address: greta.guarda@irb.usi.ch.

Classifications MeSH